NVAX Q4 2024 Earnings — Novavax, Inc. Revenue & Financial Results | Market Cap Arena

NVAXNovavax, Inc.

$2B

Q4 2024 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$88M-69.7% YoY

Gross Profit

$52M58.5% margin

Operating Income

-$131M-148.4% margin

Net Income

-$81M-91.8% margin

EPS (Diluted)

$-0.51

QoQ Revenue Growth

+4.5%

Cash Flow

Operating Cash Flow

-$173M

Free Cash Flow

-$175M

Stock-Based Comp.

$10M

Balance Sheet

Total Assets

$1.6B

Total Liabilities

$2.2B

Stockholders' Equity

-$624M

Cash & Equivalents

$530M

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$88M	$291M	-69.7%
Gross Profit	$52M	$142M	-63.8%
Operating Income	-$131M	-$184M	+28.6%
Net Income	-$81M	-$178M	+54.6%

Revenue Segments

Product

$50M56%

Royalties and Other

$39M44%

Geographic Segments

Rest of the World

$40M90%

Europe

$4M10%